Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders, 44916-44918 [E7-15495]
Download as PDF
44916
Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices
Regulations for 52 individuals. FMCSA
has statutory authority to exempt
individuals from the vision requirement
if the exemptions granted will not
compromise safety. The Agency has
reviewed the comments submitted in
response to the previous announcement
and concluded that granting these
exemption renewals will provide a level
of safety that will be equivalent to, or
greater than, the level of safety
maintained without the exemptions for
these commercial motor vehicle (CMV)
drivers.
FOR FURTHER INFORMATION CONTACT: Dr.
Mary D. Gunnels, Chief, Physical
Qualifications Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue, SE., Room W64–
224, Washington, DC 20590–0001.
Office hours are from 8:30 a.m. to 5
p.m., Monday through Friday, except
Federal holidays.
SUPPLEMENTARY INFORMATION:
Electronic Access
You may see all the comments online
through the Document Management
System (DMS) at https://dmses.dot.gov.
mstockstill on PROD1PC66 with NOTICES
Background
Under 49 U.S.C. 31136(e) and 31315,
FMCSA may grant an exemption for a 2year period if it finds ‘‘such exemption
would likely achieve a level of safety
that is equivalent to, or greater than, the
level that would be achieved absent
such exemption.’’ The statute also
allows the Agency to renew exemptions
at the end of the 2-year period. The
Notices were published on April 13,
June 13, and June 20, 2007. The
comment periods ended on May 14, and
July 13, and July 20, 2007, respectively.
Discussion of Comments
FMCSA received the same comment
in all three proceedings. The comment
was considered and discussed below.
Advocates for Highway and Auto
Safety (Advocates) expressed opposition
to FMCSA’s policy to grant exemptions
from the FMCSR, including the driver
qualification standards. Specifically,
Advocates: (1) Objects to the manner in
which FMCSA presents driver
information to the public and makes
safety determinations; (2) objects to the
Agency’s reliance on conclusions drawn
from the vision waiver program; (3)
claims the Agency has misinterpreted
statutory language on the granting of
exemptions (49 U.S.C. 31136(e) and
31315); and finally (4) suggests that a
1999 Supreme Court decision affects the
legal validity of vision exemptions.
The issues raised by Advocates were
addressed at length in 64 FR 51568
VerDate Aug<31>2005
18:25 Aug 08, 2007
Jkt 211001
(September 23, 1999), 64 FR 66962
(November 30, 1999), 64 FR 69586
(December 13, 1999), 65 FR 159 (January
3, 2000), 65 FR 57230 (September 21,
2000), and 66 FR 13825 (March 7, 2001).
We will not address these points again
here, but refer interested parties to those
earlier discussions.
Conclusion
The Agency has not received any
adverse evidence on any of these drivers
that indicates that safety is being
compromised. Based upon its
evaluation of the 52 renewal
applications, FMCSA renews the
Federal vision exemptions for Rodger B.
Anders, David F. Bardsley, Sr., Gary A.
Barrett, Ivan L. Beal, Johnny A. Beautler,
John D. Bolding, Jr., Daniel R. Brewer,
James T. Butler, Jr., Darryl D. Cassatt,
Brett L. Condon, Mark W. Coulson,
Roger K. Cox, Michael P. Curtin, Myron
D. Dixon, Albion C. Doe, Richard L.
Elyard, Michael R. Forschino, William
H. Goss, David R. Gross, James K.
Holmes, Thomas E. Howard, John R.
Hughes, Daryl A. Jester, Billy L.
Johnson, Robert L. Joiner, Jr., James P.
Jones, Christopher J. Kane, Clyde H.
Kitzan, Larry J. Lang, Dennis D.
Lesperance, John W. Locke, Herman G.
Lovell, Eugene A. Maggio, Michael L.
Manning, Clifford E. Masink, Ronald L.
Maynard, William A. Moore, Jr., Kirby
G. Oathout, James R. Petre, Danny R.
Pickelsimer, Richard C. Rehbein,
William E. Reveal, Duane L. Riendeau,
Bernard E. Roche, Darrell L. Rohlfs,
David E. Sanders, Daniel J. Schaap,
David B. Speller, Janusz Tyrpien, Lynn
D. Veach, Harry S. Warren, and Michael
C. Wines.
In accordance with 49 U.S.C. 31136(e)
and 31315, each renewal exemption will
be valid for 2 years unless revoked
earlier by FMCSA. The exemption will
be revoked if: (1) The person fails to
comply with the terms and conditions
of the exemption; (2) the exemption has
resulted in a lower level of safety than
was maintained before it was granted; or
(3) continuation of the exemption would
not be consistent with the goals and
objectives of 49 U.S.C. 31136 and 31315.
Issued on: August 2, 2007.
Larry W. Minor,
Associate Administrator for Policy and
Program Development.
[FR Doc. E7–15492 Filed 8–8–07; 8:45 am]
BILLING CODE 4910–EX–P
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2006–25854]
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption, request for comments.
AGENCY:
SUMMARY: FMCSA announces receipt of
applications from nine individuals for
an exemption from the prohibition
against persons with a clinical diagnosis
of epilepsy (or any other condition
which is likely to cause a loss of
consciousness or any loss of ability to
operate a commercial motor vehicle
(CMV)) from operating CMVs in
interstate commerce. If granted, the
exemptions would enable these
individuals with seizure disorders to
operate CMVs in interstate commerce.
DATES: Comments must be received on
or before September 10, 2007.
ADDRESSES: You may submit comments
identified by Department of
Transportation (DOT) Docket
Management System (DMS) Docket
Number FMCSA–2006–25854 using any
of the following methods:
• Web Site: https://dmses.dot.gov.
Follow the instructions for submitting
comments on the DOT electronic docket
site.
• Fax: 1–202–493–2251.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 1200
New Jersey Avenue, SE., West Building,
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: Room W12–140 on
the ground level of the West Building,
1200 New Jersey Avenue, SE.,
Washington, DC, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays.
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
on-line instructions for submitting
comments.
Instructions: All submissions must
include the Agency name and docket
number for this notice. Note that all
comments received will be posted
without change to https://dms.dot.gov,
including any personal information
provided. Please see the Privacy Act
heading below.
Docket: For access to the docket to
read background documents or
comments received, go to https://
dms.dot.gov at any time or Room W12–
E:\FR\FM\09AUN1.SGM
09AUN1
Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices
mstockstill on PROD1PC66 with NOTICES
140 on the ground level of the West
Building, 1200 New Jersey Avenue, SE.,
Washington, DC, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays. The DMS is available
24 hours each day, 365 days each year.
If you want acknowledgment that we
received your comments, please include
a self-addressed, stamped envelope or
postcard or print the acknowledgement
page that appears after submitting
comments on-line.
Privacy Act: Anyone may search the
electronic form of all comments
received into any of our dockets by the
name of the individual submitting the
comment (or of the person signing the
comment, if submitted on behalf of an
association, business, labor union, etc.).
You may review the DOT’s complete
Privacy Act Statement in the Federal
Register published on April 11, 2000
(65 FR 19477; April 11, 2000). This
information is also available at https://
dms.dot.gov.
FOR FURTHER INFORMATION CONTACT: Dr.
Mary D. Gunnels, Chief, Physical
Qualifications Division, (202) 366–4001,
maggi.gunnels@dot.gov, FMCSA, Room
W64–224, Department of
Transportation, 1200 New Jersey
Avenue, SE., Washington, DC 20590–
0001. Office hours are from 8:30 a.m. to
5 p.m., Monday through Friday, except
Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
Under 49 U.S.C. 31315 and 31136(e),
FMCSA may grant an exemption for a 2year period if it finds ‘‘such exemption
would likely achieve a level of safety
that is equivalent to, or greater than, the
level that would be achieved absent
such exemption.’’ The statute also
allows the Agency to renew exemptions
at the end of the 2-year period. The nine
individuals listed in this notice have
recently requested an exemption from
the epilepsy prohibition in 49 CFR
391.41(b)(8), which applies to drivers
who operate CMVs as defined in 49 CFR
390.5, in interstate commerce. Section
391.41(b)(8) states that a person is
physically qualified to drive a
commercial motor vehicle if that person
has no established medical history or
clinical diagnosis of epilepsy or any
other condition which is likely to cause
the loss of consciousness, or any loss of
ability to control a commercial motor
vehicle.
FMCSA provides medical advisory
criteria and guidelines for use by
medical examiners in determining
whether drivers with certain medical
conditions should be certified to operate
CMVs in interstate commerce.
VerDate Aug<31>2005
18:25 Aug 08, 2007
Jkt 211001
Currently, FMCSA’s medical advisory
criteria and guidelines include a
recommendation that individuals
diagnosed with epilepsy and taking
anticonvulsant medication to reduce the
likelihood of seizures are at high risk for
further episodes and should not be
considered for medical certification.
Individuals diagnosed with epilepsy
and taking anticonvulsant medication
which helps them control their seizures
may be at low risk of having a seizure.
However, CMV drivers are exposed to
conditions which place them at
increased risk for loss of consciousness
and therefore increased risk for seizure
occurrence, for example, obtaining or
replacing anti-seizure medication if
their medications are lost or forgotten.
This would place such drivers at some
increased risk of seizures. These
individuals should not be authorized to
drive commercial vehicles. Drivers
diagnosed with epilepsy, seizure-free
and off medication for 10 years may be
medically certified to operate CMVs.
FMCSA further recommends that
individuals who experience a single
unprovoked seizure, but who do not
have epilepsy, per se, are clearly at a
higher risk than the general population
to have further seizures. Individuals
with a single unprovoked seizure,
seizure-free for a 5-year period and off
medication, should not be restricted
from obtaining a license to operate a
CMV. The history of the occurrence of
febrile seizures in childhood should not
be a restriction to licensing to operate a
CMV. Seizures, in the context of a
systemic metabolic dysfunction, should
not be a primary reason for restriction
from medical certification to operate a
CMV. Any restriction should be based
upon the risk of recurrence of the
primary condition. There are several
conditions in which the risk for
unprovoked seizures is sufficiently
high, even in the absence of the
occurrence of acute seizures, that
medical certification should be
restricted for variable periods following
these incidents (head injury, surgical
procedures involving dural penetration,
cerebrovascular disease and infections
of the central nervous system).
44917
level of safety that is equivalent to the
level of safety obtained by complying
with the regulation because he has
remained seizure-free since 1990.
Halliard V. Brown
Mr. Brown is a store delivery driver
whose company is requesting that he
should have a federal exemption due to
his seizure disorder. He states that he
has no clinical diagnosis of epilepsy and
has had all necessary testing done. His
medical examiner certified that he has
been seizure-free for three years on his
current dose of medication.
Mr. Brown currently has a State
waiver from Ohio, continues to drive in
Ohio and has been crash-free for the
past five years.
Aaron Gillette
Mr. Gillette is a CMV driver who is
presently disqualified to perform his
duties because of the anti-seizure
medication he is taking. He has had
three seizures within the past two years.
His doctor certified that he has a history
of idiopathic epilepsy that is currently
controlled on Lamictal monotherapy; he
also noted that Mr. Gillette is
approximately 8 to 9 months seizurefree and is compliant on medications.
Mr. Gillette believes that he would
achieve a level of safety that is
equivalent to the level of safety obtained
by complying with the regulation
because he has remained seizure-free.
Summary of Application
David P. Losh
Mr. Losh is a CMV driver who has
driven in the state of Ohio for over 10
years. At the age of 5 years, he
contracted spinal meningitis which
eventually led to epileptic seizures
beginning at age 9. Mr. Losh underwent
experimental surgery in 1991 to remove
the focal point (cause) of the seizures.
He was licensed to operate a CMV in
1995 and granted an intrastate waiver
for his seizure disorder. He has had one
seizure since the surgery, on October 16,
1996; he was not taking his medication
(Dilantin) at that time. His license was
suspended for 6 months due to this
incident; he has since resumed taking
his medication. Mr. Losh has been
seizure-free and crash-free for about 10
years now.
David L. Basso
Mr. Basso is a route sales truck driver
who delivers to local grocery and
convenience stores. He states that he has
a clinical diagnosis of epilepsy and is
currently taking anti-seizure
medication. His doctor certified that he
has been seizure-free for seventeen years
on his current dose of medication. Mr.
Basso believes that he would achieve a
Dorothy R. Pokornowski
Ms. Pokornowski is a CMV driver in
the State of Minnesota. She was
diagnosed with epilepsy at age 22. Her
doctor certified that she has been stable
with no seizure activity on medication
since 1985. Her doctor also stated that
her anti-seizure medication was
changed from Phenobarbital to Topimax
in 2006 due to concerns for osteoporosis
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
E:\FR\FM\09AUN1.SGM
09AUN1
44918
Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices
and fatigue. Ms. Pokornowski has been
seizure-free and crash-free for the past
twelve years. She believes that she
would achieve a level of safety that is
equivalent to the level of safety obtained
by complying with the regulation
because she continues to take her
medication as directed by her doctor
and also gets her blood levels checked
every year.
Brian J. Porter
Mr. Porter is a CMV driver who states
that he has been driving in the east coast
for about 10 years. His neurologist states
that he has a history of seizures but has
not had any in the past 20 years. He is
currently taking Dilantin and
Phenobarbital (anti-seizure
medications).
Daniel L. Pulse
Mr. Pulse is a route sales
representative with a history of seizures
as a child following a head injury. His
doctor states that he has a history of
seizures but has not had any since 1996.
He is currently taking Dilantin (antiseizure medication). Mr. Pulse states
that he has no clinical diagnosis of
epilepsy and the medical tests
performed by his neurologist on
December 12, 2004, certify that ‘‘This is
an overall normal
electroencephalogram. No epileptiform
activity is noted’’. Mr. Pulse has been
crash-free for over 30 years. He holds a
Class B Commercial Driver’s License
(CDL) from Iowa.
mstockstill on PROD1PC66 with NOTICES
Michael W. Thomas
Mr. Thomas is a driver who was
diagnosed with seizure disorder in
1987. His doctor certified he has been
seizure-free for over 20 years. He is
currently taking Tegretol (anti-seizure
medication). His doctor certified that he
is very compliant with his treatment
and he can safely operate any CMV he
is qualified to drive. Mr. Thomas
currently has a State waiver from
Kansas, continues to drive in Kansas
and has been crash-free throughout his
commercial driving career. He holds a
Class A CDL from New York. Mr.
Thomas believes that he would achieve
a level of safety that is equivalent to the
level of safety obtained by complying
with the regulation because he has
remained seizure-free for over 20 years
through stringent medical compliance
using the same medication and dosage.
Jay A. Whitehead
Mr. Whitehead is a motor equipment
mechanic who works on CMVs. He was
diagnosed with epilepsy in 1979 and
has used medication since then. He is
currently taking Dilantin (anti-seizure
VerDate Aug<31>2005
18:48 Aug 08, 2007
Jkt 211001
medication) and has been on this
medication for more than 10 years now.
In the past 10 years, he has not had any
seizures or loss of consciousness.
Following an annual physical
examination in 2006, his doctor
certified that his seizure disorder is
stable and he has no seizure activity;
she also recommended that he should
continue to take Dilantin and
Omeprazole (anti-seizure medications).
Mr. Whitehead stated that he would be
operating a variety of CMVs after
repairing them and that the actual time
spent driving would be less than 10%
of his 8 hour work day. He holds a Class
B CDL from New York.
Request for Comments
In accordance with 49 U.S.C. 31315
and 31136(e), FMCSA requests public
comment from all interested persons on
the exemption application described in
this notice. We will consider all
comments received before the close of
business on the closing date indicated
earlier in the notice.
Issued on: August 2, 2007.
Larry W. Minor,
Associate Administrator for Policy and
Program Development.
[FR Doc. E7–15495 Filed 8–8–07; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Maritime Administration
[Docket No. MARAD–2007–28904]
Requested Administrative Waiver of
the Coastwise Trade Laws
Maritime Administration,
Department of Transportation.
ACTION: Invitation for public comments
on a requested administrative waiver of
the Coastwise Trade Laws for the vessel
MANITOU.
AGENCY:
SUMMARY: As authorized by Public Law
105–383 and Public Law 107–295, the
Secretary of Transportation, as
represented by the Maritime
Administration (MARAD), is authorized
to grant waivers of the U.S.-build
requirement of the coastwise laws under
certain circumstances. A request for
such a waiver has been received by
MARAD. The vessel, and a brief
description of the proposed service, is
listed below. The complete application
is given in DOT docket MARAD–2007–
28904 at https://dms.dot.gov. Interested
parties may comment on the effect this
action may have on U.S. vessel builders
or businesses in the U.S. that use U.S.flag vessels. If MARAD determines, in
accordance with Public Law 105–383
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
and MARAD’s regulations at 46 CFR
Part 388 (68 FR 23084; April 30, 2003),
that the issuance of the waiver will have
an unduly adverse effect on a U.S.vessel builder or a business that uses
U.S.-flag vessels in that business, a
waiver will not be granted. Comments
should refer to the docket number of
this notice and the vessel name in order
for MARAD to properly consider the
comments. Comments should also state
the commenter’s interest in the waiver
application, and address the waiver
criteria given in 388.4 of MARAD’s
regulations at 46 CFR Part 388.
DATES: Submit comments on or before
September 10, 2007.
ADDRESSES: Comments should refer to
docket number MARAD–2007–28904.
Written comments may be submitted by
hand or by mail to the Docket Clerk,
U.S. Department of Transportation,
Docket Operations, M–30, West
Building Ground Floor, Room W12–140,
1200 New Jersey Avenue, SE.,
Washington, DC 20590. You may also
send comments electronically via the
Internet at https://dmses.dot.gov/
submit/. All comments will become part
of this docket and will be available for
inspection and copying at the above
address between 10 a.m. and 5 p.m.,
E.T., Monday through Friday, except
federal holidays. An electronic version
of this document and all documents
entered into this docket is available on
the World Wide Web at https://
dms.dot.gov.
FOR FURTHER INFORMATION CONTACT:
Joann Spittle, U.S. Department of
Transportation, Maritime
Administration, 1200 New Jersey
Avenue, SE., Room W21–203,
Washington, DC 20590. Telephone 202–
366–5979.
SUPPLEMENTARY INFORMATION: As
described by the applicant the intended
service of the vessel MANITOU is:
Intended Use: ‘‘For marriages at
dockside, vow renewals and small
celebrations.’’
Geographic Region: ‘‘South shore of
Lake Superior-Bayfield, Apostles Island
area.’’
Privacy Act
Anyone is able to search the
electronic form of all comments
received into any of our dockets by the
name of the individual submitting the
comment (or signing the comment, if
submitted on behalf of an association,
business, labor union, etc.). You may
review DOT’s complete Privacy Act
Statement in the Federal Register
published on April 11, 2000 (Volume
65, Number 70; Pages 19477–78) or you
may visit https://dms.dot.gov.
E:\FR\FM\09AUN1.SGM
09AUN1
Agencies
[Federal Register Volume 72, Number 153 (Thursday, August 9, 2007)]
[Notices]
[Pages 44916-44918]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15495]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2006-25854]
Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemption, request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from nine individuals
for an exemption from the prohibition against persons with a clinical
diagnosis of epilepsy (or any other condition which is likely to cause
a loss of consciousness or any loss of ability to operate a commercial
motor vehicle (CMV)) from operating CMVs in interstate commerce. If
granted, the exemptions would enable these individuals with seizure
disorders to operate CMVs in interstate commerce.
DATES: Comments must be received on or before September 10, 2007.
ADDRESSES: You may submit comments identified by Department of
Transportation (DOT) Docket Management System (DMS) Docket Number
FMCSA-2006-25854 using any of the following methods:
Web Site: https://dmses.dot.gov. Follow the instructions
for submitting comments on the DOT electronic docket site.
Fax: 1-202-493-2251.
Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue, SE., West Building, Ground
Floor, Room W12-140, Washington, DC 20590-0001.
Hand Delivery: Room W12-140 on the ground level of the
West Building, 1200 New Jersey Avenue, SE., Washington, DC, between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays.
Federal eRulemaking Portal: Go to https://
www.regulations.gov. Follow the on-line instructions for submitting
comments.
Instructions: All submissions must include the Agency name and
docket number for this notice. Note that all comments received will be
posted without change to https://dms.dot.gov, including any personal
information provided. Please see the Privacy Act heading below.
Docket: For access to the docket to read background documents or
comments received, go to https://dms.dot.gov at any time or Room W12-
[[Page 44917]]
140 on the ground level of the West Building, 1200 New Jersey Avenue,
SE., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The DMS is available 24 hours each day, 365
days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments on-line.
Privacy Act: Anyone may search the electronic form of all comments
received into any of our dockets by the name of the individual
submitting the comment (or of the person signing the comment, if
submitted on behalf of an association, business, labor union, etc.).
You may review the DOT's complete Privacy Act Statement in the Federal
Register published on April 11, 2000 (65 FR 19477; April 11, 2000).
This information is also available at https://dms.dot.gov.
FOR FURTHER INFORMATION CONTACT: Dr. Mary D. Gunnels, Chief, Physical
Qualifications Division, (202) 366-4001, maggi.gunnels@dot.gov, FMCSA,
Room W64-224, Department of Transportation, 1200 New Jersey Avenue,
SE., Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5
p.m., Monday through Friday, except Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
Under 49 U.S.C. 31315 and 31136(e), FMCSA may grant an exemption
for a 2-year period if it finds ``such exemption would likely achieve a
level of safety that is equivalent to, or greater than, the level that
would be achieved absent such exemption.'' The statute also allows the
Agency to renew exemptions at the end of the 2-year period. The nine
individuals listed in this notice have recently requested an exemption
from the epilepsy prohibition in 49 CFR 391.41(b)(8), which applies to
drivers who operate CMVs as defined in 49 CFR 390.5, in interstate
commerce. Section 391.41(b)(8) states that a person is physically
qualified to drive a commercial motor vehicle if that person has no
established medical history or clinical diagnosis of epilepsy or any
other condition which is likely to cause the loss of consciousness, or
any loss of ability to control a commercial motor vehicle.
FMCSA provides medical advisory criteria and guidelines for use by
medical examiners in determining whether drivers with certain medical
conditions should be certified to operate CMVs in interstate commerce.
Currently, FMCSA's medical advisory criteria and guidelines include a
recommendation that individuals diagnosed with epilepsy and taking
anticonvulsant medication to reduce the likelihood of seizures are at
high risk for further episodes and should not be considered for medical
certification. Individuals diagnosed with epilepsy and taking
anticonvulsant medication which helps them control their seizures may
be at low risk of having a seizure. However, CMV drivers are exposed to
conditions which place them at increased risk for loss of consciousness
and therefore increased risk for seizure occurrence, for example,
obtaining or replacing anti-seizure medication if their medications are
lost or forgotten. This would place such drivers at some increased risk
of seizures. These individuals should not be authorized to drive
commercial vehicles. Drivers diagnosed with epilepsy, seizure-free and
off medication for 10 years may be medically certified to operate CMVs.
FMCSA further recommends that individuals who experience a single
unprovoked seizure, but who do not have epilepsy, per se, are clearly
at a higher risk than the general population to have further seizures.
Individuals with a single unprovoked seizure, seizure-free for a 5-year
period and off medication, should not be restricted from obtaining a
license to operate a CMV. The history of the occurrence of febrile
seizures in childhood should not be a restriction to licensing to
operate a CMV. Seizures, in the context of a systemic metabolic
dysfunction, should not be a primary reason for restriction from
medical certification to operate a CMV. Any restriction should be based
upon the risk of recurrence of the primary condition. There are several
conditions in which the risk for unprovoked seizures is sufficiently
high, even in the absence of the occurrence of acute seizures, that
medical certification should be restricted for variable periods
following these incidents (head injury, surgical procedures involving
dural penetration, cerebrovascular disease and infections of the
central nervous system).
Summary of Application
David L. Basso
Mr. Basso is a route sales truck driver who delivers to local
grocery and convenience stores. He states that he has a clinical
diagnosis of epilepsy and is currently taking anti-seizure medication.
His doctor certified that he has been seizure-free for seventeen years
on his current dose of medication. Mr. Basso believes that he would
achieve a level of safety that is equivalent to the level of safety
obtained by complying with the regulation because he has remained
seizure-free since 1990.
Halliard V. Brown
Mr. Brown is a store delivery driver whose company is requesting
that he should have a federal exemption due to his seizure disorder. He
states that he has no clinical diagnosis of epilepsy and has had all
necessary testing done. His medical examiner certified that he has been
seizure-free for three years on his current dose of medication.
Mr. Brown currently has a State waiver from Ohio, continues to
drive in Ohio and has been crash-free for the past five years.
Aaron Gillette
Mr. Gillette is a CMV driver who is presently disqualified to
perform his duties because of the anti-seizure medication he is taking.
He has had three seizures within the past two years. His doctor
certified that he has a history of idiopathic epilepsy that is
currently controlled on Lamictal monotherapy; he also noted that Mr.
Gillette is approximately 8 to 9 months seizure-free and is compliant
on medications. Mr. Gillette believes that he would achieve a level of
safety that is equivalent to the level of safety obtained by complying
with the regulation because he has remained seizure-free.
David P. Losh
Mr. Losh is a CMV driver who has driven in the state of Ohio for
over 10 years. At the age of 5 years, he contracted spinal meningitis
which eventually led to epileptic seizures beginning at age 9. Mr. Losh
underwent experimental surgery in 1991 to remove the focal point
(cause) of the seizures. He was licensed to operate a CMV in 1995 and
granted an intrastate waiver for his seizure disorder. He has had one
seizure since the surgery, on October 16, 1996; he was not taking his
medication (Dilantin) at that time. His license was suspended for 6
months due to this incident; he has since resumed taking his
medication. Mr. Losh has been seizure-free and crash-free for about 10
years now.
Dorothy R. Pokornowski
Ms. Pokornowski is a CMV driver in the State of Minnesota. She was
diagnosed with epilepsy at age 22. Her doctor certified that she has
been stable with no seizure activity on medication since 1985. Her
doctor also stated that her anti-seizure medication was changed from
Phenobarbital to Topimax in 2006 due to concerns for osteoporosis
[[Page 44918]]
and fatigue. Ms. Pokornowski has been seizure-free and crash-free for
the past twelve years. She believes that she would achieve a level of
safety that is equivalent to the level of safety obtained by complying
with the regulation because she continues to take her medication as
directed by her doctor and also gets her blood levels checked every
year.
Brian J. Porter
Mr. Porter is a CMV driver who states that he has been driving in
the east coast for about 10 years. His neurologist states that he has a
history of seizures but has not had any in the past 20 years. He is
currently taking Dilantin and Phenobarbital (anti-seizure medications).
Daniel L. Pulse
Mr. Pulse is a route sales representative with a history of
seizures as a child following a head injury. His doctor states that he
has a history of seizures but has not had any since 1996. He is
currently taking Dilantin (anti-seizure medication). Mr. Pulse states
that he has no clinical diagnosis of epilepsy and the medical tests
performed by his neurologist on December 12, 2004, certify that ``This
is an overall normal electroencephalogram. No epileptiform activity is
noted''. Mr. Pulse has been crash-free for over 30 years. He holds a
Class B Commercial Driver's License (CDL) from Iowa.
Michael W. Thomas
Mr. Thomas is a driver who was diagnosed with seizure disorder in
1987. His doctor certified he has been seizure-free for over 20 years.
He is currently taking Tegretol (anti-seizure medication). His doctor
certified that he is very compliant with his treatment and he can
safely operate any CMV he is qualified to drive. Mr. Thomas currently
has a State waiver from Kansas, continues to drive in Kansas and has
been crash-free throughout his commercial driving career. He holds a
Class A CDL from New York. Mr. Thomas believes that he would achieve a
level of safety that is equivalent to the level of safety obtained by
complying with the regulation because he has remained seizure-free for
over 20 years through stringent medical compliance using the same
medication and dosage.
Jay A. Whitehead
Mr. Whitehead is a motor equipment mechanic who works on CMVs. He
was diagnosed with epilepsy in 1979 and has used medication since then.
He is currently taking Dilantin (anti-seizure medication) and has been
on this medication for more than 10 years now. In the past 10 years, he
has not had any seizures or loss of consciousness. Following an annual
physical examination in 2006, his doctor certified that his seizure
disorder is stable and he has no seizure activity; she also recommended
that he should continue to take Dilantin and Omeprazole (anti-seizure
medications). Mr. Whitehead stated that he would be operating a variety
of CMVs after repairing them and that the actual time spent driving
would be less than 10% of his 8 hour work day. He holds a Class B CDL
from New York.
Request for Comments
In accordance with 49 U.S.C. 31315 and 31136(e), FMCSA requests
public comment from all interested persons on the exemption application
described in this notice. We will consider all comments received before
the close of business on the closing date indicated earlier in the
notice.
Issued on: August 2, 2007.
Larry W. Minor,
Associate Administrator for Policy and Program Development.
[FR Doc. E7-15495 Filed 8-8-07; 8:45 am]
BILLING CODE 4910-EX-P